Welcome to LookChem.com Sign In|Join Free

CAS

  • or

723-46-6

Post Buying Request

723-46-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

723-46-6 Usage

Brand Name(s) in US

Gantanol

Sulfonamide drugs

Sulfa drugs have a relative broad antimicrobial spectrum and have certain inhibitory effect against most Gram-positive bacteria and gram-negative bacteria. However, different sulfonamide drugs have different extent of antibacterial efficacy. With the wide application of sulfonamide drugs, it will also be easy to lead to resistant strains; in particular the opportunity of resistant Staphylococcus aureus will be even higher than other kinds of resistant strains. According to the absorption situations after oral administration, the sulfonamide drugs can be classified into two categories, the first category is easily absorbed sulfonamide drugs, which is characterized by rapid absorption. Generally, their plasma concentrations can reach peak at 2-4 hours after the administration (5 hour for long-acting drugs). This kind of sulfonamide drugs are mainly used for systemic infections. Another kind of drugs is hardly or poorly absorbed after oral administration with most of them being excreted through the intestinal tract and is mainly used for treating intestinal infections. Sulfamethoxazole is a broad-spectrum antibiotic with particularly strong efficacy on Staphylococcus aureus and Escherichia coli and can be used for the treatment of urinary tract infections and fowl cholera. Sulfamethoxazole belongs to a systemic, moderate sulfonamide drug. It can compete with PABA through taking effect on the bacterial in vivo dihydrofolate synthase, preventing the bacterial synthesis of dihydrofolate and thereby inhibiting the bacterial growth and reproduction. It, together with other three kinds of sulfonamide drugs: sulfadiazine, sulfisoxazole and trisulfapyrimidine are currently excellent drugs for the treatment of nocardiosis. It has a half-life of 10 to 12 hours and can be partially acetylated. This product, although has the number of required medication be less than sulfisoxazole (2 times per day instead of four times), but its acetylated metabolites has a low solubility in the urine so the likelihood of large crystals formation in urine is bit higher. Patients should maintain enough hydrated conditions (the daily adult urine output should be not less than 1,500ml). When being used in combination with the synergist trimethoprim, its antibacterial activity can get significantly enhanced. Sulfamethoxazole compound (sulfamethoxazole/trimethoprim namely SMZ/TMP) can often give better efficacy than monotherapy (see dihydrofolate reductase inhibitors). Clinically it is commonly used for the treatment of urinary tract infections, respiratory tract infections, typhoid, and salmonella infections, Pneumocystis carinii echinococcosis and nocardiosis. It can also be used for preventing meningococcal meningitis. Some clinicians advocate use minocycline, erythromycin or ampicillin in combination with sulfamethoxazole to treat such infections. However, there has been no clinical data for proving that combination therapy is superior to single administration of sulfonamide. Sulfamethoxazole compound (TMP/SMZ), minocycline (Minocin) and amikacin can also be used for the treatment of nocardia infection.

Mechanism of action

It is known that bacterial can synthesize thymidine, purine and finally synthesize DNA and need folic acid derivatives, tetrahydrofolate as cofactors. Most bacterial cells can’t allow the penetration of folic acid and instead needs the synthesis through aminobenzoic acid (PABA). Sulfonamide has a similar structure to PABA and thus can competitively inhibit the synthesis of the direct precursor of dihydrofolate, dihy-dropteroic acid through the reaction between PABA and pteridine. Mammalian cells, instead, is not inhibited since they require preformed folate and is not capable of synthesizing this product. Treatment concentration of sulfonamide drug sulfamethoxazole is primarily bacteriostatic agents. However, when the bacteria is grown in the medium containing purine, amino aicd but very low concentration of thymine, the sulfonamide drugs can produce a bactericidal effect, that is, "thymine lethal defect". This bactericidal effect has been demonstrated in human blood and urine (Then and Angehrn, 1973 A and B; see also Pratt and Fekety, 1986). The effect of sulfonamide drug-induced inhibition of bacterial cell growth can be reversed upon supplement in vitro of some substances (such as thymidine, purines, methionine and serine) to the growth medium. This may have important clinical significance. Because the pus generated by cells destruction may contain a large amount of these substances. It is therefore, upon purulent infection, the effect of the drug may be inhibited probably due to the presence of such substances. Furthermore, for the in vitro susceptibility testing, the medium can’t contain PABA for which even in trace amount, the test results can be disturbed. The above information is edited by the lookchem of Dai Xiongfeng.

Chemical Properties

Different sources of media describe the Chemical Properties of 723-46-6 differently. You can refer to the following data:
1. It is white crystalline powder and is odorless with slightly bitter taste. It has a melting point of 168 ℃. It is very slightly soluble in water, soluble in dilute acid, dilute alkali or ammonia.
2. solid

Uses

Different sources of media describe the Uses of 723-46-6 differently. You can refer to the following data:
1. As an antimicrobial agent, it is particularly effective in treating Staphylococcus aureus and E. coli. It is mainly used for the treatment of fowl cholera. It can be used as anti-infective drug and can be used for the treatment and prevention of acute and chronic urinary tract infections, respiratory infections, intestinal infections, Salmonella infections, children acute otitis media, and meningitis.
2. An antibacterial drug. Sulfonamide antibiotic that blocks the synthesis of dihydrofolic acid by inhibiting the enzyme dihydropteroate synthase.
3. antibacterial, antipneumocystis
4. An antibacterial drug. Sulfonamide antibiotic that blocks the synthesis of dihydrofolic acid by inhibiting the enzyme dihydropteroate synthase.This compound is a contaminant of emerging concern (CECs).

Production method

It can be produced from 5-methyl-isobutyl-3-carboxamide via degradation, condensation and hydrolysis successively. Use 5-methyl-isobutyl-3-carboxamide as raw materials, it is degraded into 5-methyl-isoxazol-3 amine under the action of sodium hypochlorite solution, then condense with para-acetamidophenoxymethyl chloride to generate 3-(p-acetamide benzenesulfonamido)-5-methylisoxazole with further hydrolysis under alkaline conditions to give 3-(p-amino benzenesulfonamido)-5-methylisoxazole.

Description

Like sulfisoxazole, this drug is effective in treating infections caused by streptococci, gonococci, pneumococci, staphylococci as well as colon bacillus. Unlike sulfisoxazole, only about 70% of it binds with proteins in the plasma after oral administration, and it diffuses mostly to tissues and tissue fluids. However, since it is removed much slower than sulfisoxazole, it does not require frequent administration and is also the drug of choice for many systemic infections. Moreover, it is an ingredient of a combined drug named bactrim, biseptol, and so on (which will be examined later on), which has a fixed correlation with trimethoprim. Synonyms of this drug are gantanol, sinomin, sulfisomezole, and others.

Definition

ChEBI: An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.

Brand name

Gantanol (Roche); Urobak (Shionogi).

Antimicrobial activity

The intrinsic activity is similar to that of sulfadiazine.

General Description

Sulfamethoxazole’s plasma half-life is 11 hours. Sulfamethoxazole is a sulfonamide drug closely relatedto sulfisoxazole in chemical structure and antimicrobial activity.It occurs as a tasteless, odorless, almost white crystallinepowder. The solubility of sulfamethoxazole in the pHrange of 5.5 to 7.4 is slightly lower than that of sulfisoxazole but higher than that of sulfadiazine, sulfamerazine, or sulfamethazine.Following oral administration, sulfamethoxazole is notabsorbed as completely or as rapidly as sulfisoxazole, andits peak blood level is only about 50% as high.

Air & Water Reactions

Insoluble in water.

Fire Hazard

Flash point data for Sulfamethoxazole are not available but Sulfamethoxazole is probably non-flammable.

Pharmaceutical Applications

This is the sulfonamide component of co-trimoxazole. It is slightly soluble in water.

Pharmacokinetics

Oral absorption: 85% Cmax 800 mg oral: c.50 mg/L after 3–6 h Plasma half-life: 6–20 h Volume of distribution: 12–18 L Plasma protein binding: 65% Penetration of extravascular sites, including the CSF, is good. It crosses the placenta and achieves levels in breast milk of about 10% of the simultaneous plasma concentration. It is extensively metabolized, but about 30% of the dose is excreted unchanged in urine so that high concentrations are achieved.

Clinical Use

Sulfamethoxazole is used only in combination with the diaminopyrimidine trimethoprim.

Side effects

Unwanted effects are those common to sulfonamides. In addition, benign intracranial hypertension has been reported in children. Most side effects of co-trimoxazole are thought to be attributable to the sulfonamide component.

Safety Profile

Moderately toxic by ingestion and intraperitoneal routes. Questionable carcinogen with experimental tumorigenic data. When heated to decomposition it emits very toxic fumes of NOx and SOx.

Synthesis

Sulfamethoxazole, N1 -(5-methyl-3-isoxazolyl)sulfanilamide (33.1.20), is synthesized by a completely analogous scheme, except by using 3-amino-5-methylisoxazol as the heterocyclic component.

Check Digit Verification of cas no

The CAS Registry Mumber 723-46-6 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 7,2 and 3 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 723-46:
(5*7)+(4*2)+(3*3)+(2*4)+(1*6)=66
66 % 10 = 6
So 723-46-6 is a valid CAS Registry Number.
InChI:InChI=1/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)

723-46-6 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (S0361)  Sulfamethoxazole  >98.0%(HPLC)(T)

  • 723-46-6

  • 25g

  • 460.00CNY

  • Detail
  • Sigma-Aldrich

  • (PHR1126)    pharmaceutical secondary standard; traceable to USP, PhEur and BP

  • 723-46-6

  • PHR1126-1G

  • 732.19CNY

  • Detail
  • Sigma-Aldrich

  • (76177)  Sulfamethoxazole  certified reference material, TraceCERT®

  • 723-46-6

  • 76177-100MG

  • 1,055.34CNY

  • Detail
  • Sigma-Aldrich

  • (S2100000)  Sulfamethoxazole  European Pharmacopoeia (EP) Reference Standard

  • 723-46-6

  • S2100000

  • 1,880.19CNY

  • Detail
  • USP

  • (1631001)  Sulfamethoxazole  United States Pharmacopeia (USP) Reference Standard

  • 723-46-6

  • 1631001-200MG

  • 4,581.72CNY

  • Detail
  • Sigma-Aldrich

  • (S7507)  Sulfamethoxazole  analytical standard

  • 723-46-6

  • S7507-10G

  • 380.25CNY

  • Detail
  • Sigma-Aldrich

  • (S7507)  Sulfamethoxazole  analytical standard

  • 723-46-6

  • S7507-100G

  • 1,964.43CNY

  • Detail
  • Sigma-Aldrich

  • (31737)  Sulfamethoxazole  VETRANAL, analytical standard

  • 723-46-6

  • 31737-250MG

  • 360.36CNY

  • Detail

723-46-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name sulfamethoxazole

1.2 Other means of identification

Product number -
Other names 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:723-46-6 SDS

723-46-6Synthetic route

N-acetylsulfamethoxazole
21312-10-7

N-acetylsulfamethoxazole

sulfamethoxazole
723-46-6

sulfamethoxazole

Conditions
ConditionsYield
With hydrogenchloride In methanol; diethyl ether at 75℃; for 0.25h; Microwave irradiation;100%
Stage #1: N-acetylsulfamethoxazole With sodium hydroxide; water at 80℃; for 1h;
Stage #2: With acetic acid In water pH=6;
96%
With sodium hydroxide In water for 4h; Reflux;93%
5-methylisoxazol-3-ylamine
1072-67-9

5-methylisoxazol-3-ylamine

4-aminobenzenesulfonyl chloride
24939-24-0

4-aminobenzenesulfonyl chloride

sulfamethoxazole
723-46-6

sulfamethoxazole

Conditions
ConditionsYield
Stage #1: 5-methylisoxazol-3-ylamine With ammonium hydroxide at 35 - 40℃; for 1h; Large scale;
Stage #2: 4-aminobenzenesulfonyl chloride at 15 - 20℃; for 4.5h; Large scale;
95%
5-methylisoxazol-3-ylamine
1072-67-9

5-methylisoxazol-3-ylamine

p-acetylaminobenzenesulfonyl chloride
121-60-8

p-acetylaminobenzenesulfonyl chloride

sulfamethoxazole
723-46-6

sulfamethoxazole

Conditions
ConditionsYield
Stage #1: 5-methylisoxazol-3-ylamine; p-acetylaminobenzenesulfonyl chloride With pyridine In tetrahydrofuran at 20℃; Inert atmosphere;
Stage #2: With sodium hydroxide for 2h; Inert atmosphere; Reflux;
60%
Stage #1: 5-methylisoxazol-3-ylamine; p-acetylaminobenzenesulfonyl chloride With pyridine In tetrahydrofuran at 20℃; for 6h;
Stage #2: With sodium hydroxide for 2h; Reflux;
4-amino-N-(5-methyl-3-isoxazolyl)-benzene sulfonamide
13053-79-7

4-amino-N-(5-methyl-3-isoxazolyl)-benzene sulfonamide

A

sulfamethoxazole
723-46-6

sulfamethoxazole

B

C10H11N3O3S
954563-97-4

C10H11N3O3S

C

C10H11N3O3S

C10H11N3O3S

Conditions
ConditionsYield
Stage #1: 4-amino-N-(5-methyl-3-isoxazolyl)-benzene sulfonamide With tris(2,2-bipyridine)ruthenium(II) hexafluorophosphate; C8H9F3NO3S(1+)*CF3O3S(1-) In acetonitrile at 30℃; for 1h; Sealed tube; Irradiation;
Stage #2: With N-butylamine In acetonitrile at 23℃; for 12h; regioselective reaction;
A 13%
B 43%
C 12%
N,N'-bis-(5-methyl-isoxazol-3-yl)-4,4'-diazenediyl-bis-benzenesulfonamide
97254-40-5

N,N'-bis-(5-methyl-isoxazol-3-yl)-4,4'-diazenediyl-bis-benzenesulfonamide

sulfamethoxazole
723-46-6

sulfamethoxazole

Conditions
ConditionsYield
With hydrogen; nickel In sodium hydroxide Ambient temperature;
2-butynenitrile
13752-78-8

2-butynenitrile

p-acetylaminobenzenesulfonyl chloride
121-60-8

p-acetylaminobenzenesulfonyl chloride

sulfamethoxazole
723-46-6

sulfamethoxazole

Conditions
ConditionsYield
(i) NH2OH*HCl, aq. NaOH, EtOH, (ii) /BRN= 746676/, Py, (iii) aq. NaOH; Multistep reaction;
2,3-dibromobutanenitrile
25109-76-6

2,3-dibromobutanenitrile

p-acetylaminobenzenesulfonyl chloride
121-60-8

p-acetylaminobenzenesulfonyl chloride

sulfamethoxazole
723-46-6

sulfamethoxazole

Conditions
ConditionsYield
(i) NH2CONHOH, aq. NaOH, K2CO3, (ii) /BRN= 746676/, Py, (iii) aq. NaOH; Multistep reaction;
N-(5-methyl-isoxazol-3-yl)-4-nitro-benzenesulfonamide
29699-89-6

N-(5-methyl-isoxazol-3-yl)-4-nitro-benzenesulfonamide

sulfamethoxazole
723-46-6

sulfamethoxazole

Conditions
ConditionsYield
With hydrogen; platinum In ethanol Ambient temperature;
Multi-step reaction with 2 steps
1: H2 / Pd-C / aq. NaOH / Ambient temperature
2: H2 / Raney-Ni / aq. NaOH / Ambient temperature
View Scheme
glutathione
128960-77-0

glutathione

nitroso derivative of sulfamethoxazole
131549-85-4

nitroso derivative of sulfamethoxazole

A

sulfamethoxazole
723-46-6

sulfamethoxazole

B

glutathione disulfide
464195-31-1

glutathione disulfide

C

(S)-2-Amino-4-[(S)-1-(carboxymethyl-carbamoyl)-2-sulfino-ethylcarbamoyl]-butyric acid

(S)-2-Amino-4-[(S)-1-(carboxymethyl-carbamoyl)-2-sulfino-ethylcarbamoyl]-butyric acid

D

(S)-2-Amino-4-((S)-1-(carboxymethyl-carbamoyl)-2-{N-[4-(5-methyl-isoxazol-3-ylsulfamoyl)-phenyl]aminosulfanyl}-ethylcarbamoyl)-butyric acid

(S)-2-Amino-4-((S)-1-(carboxymethyl-carbamoyl)-2-{N-[4-(5-methyl-isoxazol-3-ylsulfamoyl)-phenyl]aminosulfanyl}-ethylcarbamoyl)-butyric acid

E

C20H26N6O10S2

C20H26N6O10S2

F

(S)-2-Amino-4-{(S)-1-(carboxymethyl-carbamoyl)-2-[4-(5-methyl-isoxazol-3-ylsulfamoyl)-phenylsulfinamoyl]-ethylcarbamoyl}-butyric acid

(S)-2-Amino-4-{(S)-1-(carboxymethyl-carbamoyl)-2-[4-(5-methyl-isoxazol-3-ylsulfamoyl)-phenylsulfinamoyl]-ethylcarbamoyl}-butyric acid

Conditions
ConditionsYield
In dimethyl sulfoxide for 20h; Product distribution;
5-methylisoxazol-3-ylamine
1072-67-9

5-methylisoxazol-3-ylamine

4-chlorosulfonylbenzene isocyanate
6752-38-1

4-chlorosulfonylbenzene isocyanate

sulfamethoxazole
723-46-6

sulfamethoxazole

Conditions
ConditionsYield
solid phase synthesis; Yield given. Multistep reaction;
sulphamethoxazole hydroxylamine
114438-33-4

sulphamethoxazole hydroxylamine

sulfamethoxazole
723-46-6

sulfamethoxazole

Conditions
ConditionsYield
With 1,4-dihydronicotinamide adenine dinucleotide; human recombinant NADH cytochrome b5 reductase; cytochrome b5 In dimethyl sulfoxide pH=7.4; Enzyme kinetics; Further Variations:; Reagents;
With nicotinamide-adenin-dinucleotide reduced; recombinant human mitochondrial amidoxime reducing component-2 wild type protein In aq. buffer at 37℃; for 0.333333h; pH=6; Kinetics; Reagent/catalyst; Enzymatic reaction;
p-acetylaminobenzenesulfonyl chloride
121-60-8

p-acetylaminobenzenesulfonyl chloride

sulfamethoxazole
723-46-6

sulfamethoxazole

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: pyridine
2: aqueous NaOH
View Scheme
Multi-step reaction with 2 steps
1: pyridine / dichloromethane / 18 h / 20 °C / Inert atmosphere
2: hydrogenchloride / diethyl ether; methanol / 0.25 h / 75 °C / Microwave irradiation
View Scheme
Multi-step reaction with 2 steps
1: pyridine; dmap / 12 h / 20 °C
2: sodium hydroxide / water / 4 h / Reflux
View Scheme
Multi-step reaction with 2 steps
1: potassium carbonate / acetonitrile / 2 h / Reflux
2: hydrogenchloride / water / 3 h
View Scheme
4-Nitrobenzenesulfonyl chloride
98-74-8

4-Nitrobenzenesulfonyl chloride

sulfamethoxazole
723-46-6

sulfamethoxazole

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: pyridine / 6 h / Ambient temperature
2: H2 / Pd-C / aq. NaOH / Ambient temperature
3: H2 / Raney-Ni / aq. NaOH / Ambient temperature
View Scheme
Multi-step reaction with 2 steps
1: pyridine / 6 h / Ambient temperature
2: H2 / Pt / ethanol / Ambient temperature
View Scheme
4,4'-diazenediyl-bis-benzenesulfonyl chloride
99447-77-5

4,4'-diazenediyl-bis-benzenesulfonyl chloride

sulfamethoxazole
723-46-6

sulfamethoxazole

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: pyridine / 1 h / Heating
2: H2 / Raney-Ni / aq. NaOH / Ambient temperature
View Scheme
Acetanilid
103-84-4

Acetanilid

sulfamethoxazole
723-46-6

sulfamethoxazole

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: chlorosulfonic acid / 10 h / 15 - 50 °C
2.1: sodium chloride / water / 40 °C
2.2: 5 h / 25 - 38 °C / pH 4
3.1: sodium hydroxide / water / 2 h / 104 °C / pH 14
View Scheme
sulfamethoxazole
723-46-6

sulfamethoxazole

1-n-butyl-3-methylimidazolim bromide
85100-77-2

1-n-butyl-3-methylimidazolim bromide

C8H15N2(1+)*C10H10N3O3S(1-)
1676076-93-9

C8H15N2(1+)*C10H10N3O3S(1-)

Conditions
ConditionsYield
Stage #1: 1-n-butyl-3-methylimidazolim bromide With Merck ion exchange resin III In water
Stage #2: sulfamethoxazole In water at 20℃; for 2h;
99%
pyrrolidine
123-75-1

pyrrolidine

sulfamethoxazole
723-46-6

sulfamethoxazole

C15H18N4O3S

C15H18N4O3S

Conditions
ConditionsYield
Stage #1: sulfamethoxazole With hydrogenchloride; sodium nitrite Green chemistry;
Stage #2: pyrrolidine With potassium hydroxide Green chemistry;
99%
sulfamethoxazole
723-46-6

sulfamethoxazole

silver(I) trifluoromethanethiolate
811-68-7

silver(I) trifluoromethanethiolate

4-isothiocyanato-N-(5-methylisoxazol-3-yl)benzenesulfonamide
956576-66-2

4-isothiocyanato-N-(5-methylisoxazol-3-yl)benzenesulfonamide

Conditions
ConditionsYield
With potassium bromide In acetonitrile at 20℃; for 1h;97%
4-(4-hydroxybenzylidene)-2-phenyloxazol-5(4H)-one
1226-71-7, 57427-89-1, 82301-52-8

4-(4-hydroxybenzylidene)-2-phenyloxazol-5(4H)-one

sulfamethoxazole
723-46-6

sulfamethoxazole

C26H20N4O5S
843640-21-1

C26H20N4O5S

Conditions
ConditionsYield
Stage #1: 4-(4-hydroxybenzylidene)-2-phenyloxazol-5(4H)-one; sulfamethoxazole at 140℃; for 1h;
Stage #2: In acetone for 8h; Reflux;
93%
sulfamethoxazole
723-46-6

sulfamethoxazole

1-octyl-3-methyl-imidazolium bromide

1-octyl-3-methyl-imidazolium bromide

C12H23N2(1+)*C10H10N3O3S(1-)
1676076-98-4

C12H23N2(1+)*C10H10N3O3S(1-)

Conditions
ConditionsYield
Stage #1: 1-octyl-3-methyl-imidazolium bromide With Merck ion exchange resin III In water
Stage #2: sulfamethoxazole In water at 20℃; for 2h;
93%
3,5-diodosalicylaldehyde
2631-77-8

3,5-diodosalicylaldehyde

sulfamethoxazole
723-46-6

sulfamethoxazole

4-[(2-hydroxy-3,5-diiodobenzylidene)amino]-N-(5-methylisoxazol-3-yl)benzenesulfonamide

4-[(2-hydroxy-3,5-diiodobenzylidene)amino]-N-(5-methylisoxazol-3-yl)benzenesulfonamide

Conditions
ConditionsYield
In methanol at 20℃; for 16h; Reflux;93%
sulfamethoxazole
723-46-6

sulfamethoxazole

(1,1,1,3,3,3-hexafluoro-2-methylprop-2-yl)isocyanate
19755-56-7

(1,1,1,3,3,3-hexafluoro-2-methylprop-2-yl)isocyanate

1-[4-[(5-methylisoxazol-3-yl)sulfamoyl]phenyl]-3-[2,2,2-trifluoro-1-methyl-1-(trifluoromethyl)ethyl]urea
355829-57-1

1-[4-[(5-methylisoxazol-3-yl)sulfamoyl]phenyl]-3-[2,2,2-trifluoro-1-methyl-1-(trifluoromethyl)ethyl]urea

Conditions
ConditionsYield
With triethylamine In diethyl ether; benzene at 100℃;92%
N-(2-chloropyrimidin-4-yl)-2,3-dimethyl-2H-indazol-6-amine
444731-74-2

N-(2-chloropyrimidin-4-yl)-2,3-dimethyl-2H-indazol-6-amine

sulfamethoxazole
723-46-6

sulfamethoxazole

4-((4-((2,3-dimethyl-2H-indazol-6-yl)amino)pyrimidin-2-yl)amino)-N-(5-methylisoxazol-3-yl)benzenesulfonamide
1572439-33-8

4-((4-((2,3-dimethyl-2H-indazol-6-yl)amino)pyrimidin-2-yl)amino)-N-(5-methylisoxazol-3-yl)benzenesulfonamide

Conditions
ConditionsYield
With hydrogenchloride In water; isopropyl alcohol at 85℃;92%
1-hexadecyl-3-methyl-3H-imidazol-1-ium; bromide

1-hexadecyl-3-methyl-3H-imidazol-1-ium; bromide

sulfamethoxazole
723-46-6

sulfamethoxazole

C20H39N2(1+)*C10H10N3O3S(1-)
1676077-01-2

C20H39N2(1+)*C10H10N3O3S(1-)

Conditions
ConditionsYield
Stage #1: 1-hexadecyl-3-methyl-3H-imidazol-1-ium; bromide With Merck ion exchange resin III In water
Stage #2: sulfamethoxazole In water at 20℃; for 2h;
92%
Propyl isocyanate
110-78-1

Propyl isocyanate

sulfamethoxazole
723-46-6

sulfamethoxazole

N-(5-methylisoxazol-3-yl)-4-(3-propylureido)benzenesulfonamide

N-(5-methylisoxazol-3-yl)-4-(3-propylureido)benzenesulfonamide

Conditions
ConditionsYield
In acetonitrile at 20℃; for 11.5h; Reflux;92%
sulfamethoxazole
723-46-6

sulfamethoxazole

diazepam
439-14-5

diazepam

4-([4-{7-chloro-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl}phenyl]diazenyl)-N-(5-methylisoxazol-3-yl)benzenesulfonamide

4-([4-{7-chloro-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl}phenyl]diazenyl)-N-(5-methylisoxazol-3-yl)benzenesulfonamide

Conditions
ConditionsYield
Stage #1: sulfamethoxazole With hydrogenchloride; sodium nitrite In water at 0 - 5℃; for 0.0833333h; Green chemistry;
Stage #2: diazepam With sodium acetate In ethanol; water Green chemistry;
92%
sulfamethoxazole
723-46-6

sulfamethoxazole

trimethylsulfoxonium iodide
1774-47-6

trimethylsulfoxonium iodide

4-amino-N-(5-methyl-3-isoxazolyl)-N-methylbenzenesulfonamide
51543-31-8

4-amino-N-(5-methyl-3-isoxazolyl)-N-methylbenzenesulfonamide

Conditions
ConditionsYield
With aluminum oxide; potassium hydroxide at 130℃; for 0.0666667h; microwave irradiation;91%
sulfamethoxazole
723-46-6

sulfamethoxazole

benzyl isothiocyanate
3173-56-6

benzyl isothiocyanate

4-(3-benzylureido)-N-(5-methylisoxazol-3-yl)benzenesulfonamide

4-(3-benzylureido)-N-(5-methylisoxazol-3-yl)benzenesulfonamide

Conditions
ConditionsYield
In acetonitrile at 20℃; for 11.5h; Reflux;91%
In N,N-dimethyl-formamide at 90 - 100℃;2.12 g
sulfamethoxazole
723-46-6

sulfamethoxazole

4-azido-N-(5-methylisoxazol-3-yl)benzenesulfonamide

4-azido-N-(5-methylisoxazol-3-yl)benzenesulfonamide

Conditions
ConditionsYield
Stage #1: sulfamethoxazole With sulfuric acid In water at 0℃;
Stage #2: With sodium nitrite In water at 0 - 20℃; for 0.166667h;
Stage #3: With sodium azide; urea In water at 20℃;
91%
With sodium azide; tert.-butylnitrite In 1,4-dioxane; water at 50℃; for 0.333333h; Microwave irradiation;82%
sulfamethoxazole
723-46-6

sulfamethoxazole

C10H10(2)HN3O3S

C10H10(2)HN3O3S

Conditions
ConditionsYield
With Kerr's catalyst; deuterium In chlorobenzene at 120℃; for 1h;91%
formaldehyd
50-00-0

formaldehyd

sulfamethoxazole
723-46-6

sulfamethoxazole

N-(4-carbamoylphenyl)nicotinamide
418790-13-3

N-(4-carbamoylphenyl)nicotinamide

N-[4-({[4-(5-methyl-isoxazol-3-ylsulfamoyl)-phenylamino]-methyl}-carbamoyl)-phenyl]-nicotinamide

N-[4-({[4-(5-methyl-isoxazol-3-ylsulfamoyl)-phenylamino]-methyl}-carbamoyl)-phenyl]-nicotinamide

Conditions
ConditionsYield
Stage #1: formaldehyd; N-(4-carbamoyl-phenyl)-nicotinamide With hydrogenchloride In methanol at 0℃; for 0.5h; pH=3.5;
Stage #2: sulfamethoxazole Heating;
90%
sulfamethoxazole
723-46-6

sulfamethoxazole

3-methoxy-2-hydroxybenzaldehyde
148-53-8

3-methoxy-2-hydroxybenzaldehyde

4-(2-hydroxy-3-methoxybenzylidenamine)-N-(5-methylisoxozaol-3-yl)benzenesulfonamide
328026-18-2

4-(2-hydroxy-3-methoxybenzylidenamine)-N-(5-methylisoxozaol-3-yl)benzenesulfonamide

Conditions
ConditionsYield
In tetrahydrofuran for 2h;90%
With acetic acid In ethanol for 1h; Reflux;81%
methyl 2-[4-(1H-indol-2-yl)phenoxy]acetate
1357149-34-8

methyl 2-[4-(1H-indol-2-yl)phenoxy]acetate

sulfamethoxazole
723-46-6

sulfamethoxazole

2-[4-(1H-indol-2-yl)phenoxy]-N-{4-[N-(5-methylisoxazol-3-yl)sulfamoyl]phenyl}acetamide
1357149-22-4

2-[4-(1H-indol-2-yl)phenoxy]-N-{4-[N-(5-methylisoxazol-3-yl)sulfamoyl]phenyl}acetamide

Conditions
ConditionsYield
With potassium carbonate In acetone for 10h;90%
N-Hydroxymethylisatin
50899-59-7

N-Hydroxymethylisatin

sulfamethoxazole
723-46-6

sulfamethoxazole

4-[(1-hydroxymethyl)-2-oxindolin-3-ylideneamino]-N-(5-methylisoxazol-3-yl)benzenesulphonamide
1393098-78-6

4-[(1-hydroxymethyl)-2-oxindolin-3-ylideneamino]-N-(5-methylisoxazol-3-yl)benzenesulphonamide

Conditions
ConditionsYield
In ethanol for 8h; Reflux;90%
sulfamethoxazole
723-46-6

sulfamethoxazole

1-cyanoacetyl-3,5-dimethylpyrazole
36140-83-7

1-cyanoacetyl-3,5-dimethylpyrazole

2-cyano-N-(4-{[(5-methylisoxazol-3-yl)amino]sulfonyl}phenyl)acetamide
901373-59-9

2-cyano-N-(4-{[(5-methylisoxazol-3-yl)amino]sulfonyl}phenyl)acetamide

Conditions
ConditionsYield
In toluene for 3h; Reflux;90%
In 1,4-dioxane for 3h; Reflux;80%
sulfamethoxazole
723-46-6

sulfamethoxazole

3,5-disulfamethoxazole curcumin
1443768-38-4

3,5-disulfamethoxazole curcumin

Conditions
ConditionsYield
With acetic acid In ethanol at 60℃; for 2h;90%
sulfamethoxazole
723-46-6

sulfamethoxazole

phenyl isocyanate
103-71-9

phenyl isocyanate

N-(5-methylisoxazol-3-yl)-4-(3-phenylureido)benzenesulfonamide

N-(5-methylisoxazol-3-yl)-4-(3-phenylureido)benzenesulfonamide

Conditions
ConditionsYield
In acetonitrile at 20℃; for 11.5h; Reflux;90%
In N,N-dimethyl-formamide at 90 - 100℃;1.74 g
sulfamethoxazole
723-46-6

sulfamethoxazole

salicylaldehyde
90-02-8

salicylaldehyde

4-[(3-formyl-4-hydroxyphenyl)diazenyl]-N-(5-methylisoxazol-3-yl)benzenesulfonamide

4-[(3-formyl-4-hydroxyphenyl)diazenyl]-N-(5-methylisoxazol-3-yl)benzenesulfonamide

Conditions
ConditionsYield
Stage #1: sulfamethoxazole With hydrogenchloride; sodium nitrite at 0 - 5℃;
Stage #2: salicylaldehyde With sodium hydroxide In water
90%
Stage #1: sulfamethoxazole With hydrogenchloride In water for 0.5h;
Stage #2: With sodium nitrite In water at 0 - 5℃;
Stage #3: salicylaldehyde With hydrogenchloride; potassium hydroxide In water Cooling with ice;
sulfamethoxazole
723-46-6

sulfamethoxazole

dimedone
126-81-8

dimedone

4‐((5,5‐dimethyl‐3‐oxocyclohex‐1‐en‐1‐yl)amino)‐N‐(5‐methylisoxazol‐3‐yl)benzenesulfonamide

4‐((5,5‐dimethyl‐3‐oxocyclohex‐1‐en‐1‐yl)amino)‐N‐(5‐methylisoxazol‐3‐yl)benzenesulfonamide

Conditions
ConditionsYield
With trichloroacetic acid at 140℃; for 0.25h;90%
sulfamethoxazole
723-46-6

sulfamethoxazole

mercury(II) diacetate
1600-27-7

mercury(II) diacetate

Hg(sulfamethoxazolato)2

Hg(sulfamethoxazolato)2

Conditions
ConditionsYield
In methanol Hg(II) acetate in methanol added dropwise with stirring; stirred (18 h,room temp.); filtered off; air dried; elem. anal.;89%
sulfamethoxazole
723-46-6

sulfamethoxazole

4-(4-methoxybenzylidene)-2-phenyl-5(4H)-oxazolone
5429-22-1

4-(4-methoxybenzylidene)-2-phenyl-5(4H)-oxazolone

C27H22N4O5S
843640-09-5

C27H22N4O5S

Conditions
ConditionsYield
Stage #1: sulfamethoxazole; 4-(4-methoxybenzylidene)-2-phenyl-5(4H)-oxazolone at 140℃; for 1h;
Stage #2: In acetone for 8h; Reflux;
89%
sulfamethoxazole
723-46-6

sulfamethoxazole

3-sulfamethoxazole curcumin
1443768-33-9

3-sulfamethoxazole curcumin

Conditions
ConditionsYield
In ethanol at 60℃; for 4h;89%
2,5-dioxopyrrolidin-1-yl methylcarbamate
18342-66-0

2,5-dioxopyrrolidin-1-yl methylcarbamate

sulfamethoxazole
723-46-6

sulfamethoxazole

N-(5-methylisoxazol-3-yl)-4-(3-methylureido)benzenesulfonamide

N-(5-methylisoxazol-3-yl)-4-(3-methylureido)benzenesulfonamide

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In acetonitrile for 24h;89%

723-46-6Relevant articles and documents

Reduction of sulfamethoxazole hydroxylamine (SMX-HA) by the mitochondrial amidoxime reducing component (mARC)

Ott, Gudrun,Plitzko, Birte,Krischkowski, Carmen,Reichmann, Debora,Bittner, Florian,Mendel, Ralf R.,Kunze, Thomas,Clement, Bernd,Havemeyer, Antje

, p. 1687 - 1695 (2014)

Under high dose treatment with sulfamethoxazole (SMX)/trimethoprim (TMP), hypersensitivity reactions occur with a high incidence. The mechanism of this adverse drug reaction is not fully understood. Several steps in the toxification pathway of SMX were investigated. The aim of our study was to investigate the reduction of sulfamethoxazole hydroxylamine (SMX-HA) in this toxification pathway, which can possibly be catalyzed by the mARC-containing N-reductive enzyme system. Western blot analyses of subcellular fractions of porcine tissue were performed with antibodies against mARC-1, mARC-2, cytochrome b5 type B, and NADH cytochrome b5 reductase. Incubations of porcine and human subcellular tissue fractions and of the heterologously expressed human components of the N-reductive enzyme system were carried out with SMX-HA. mARC-1 and mARC-2 knockdown was performed in HEK-293 cells. Kinetic parameters of the heterologously expressed human protein variants V96L, A165T, M187 K, C246S, D247H, and M268I of mARC-1 and G244S and C245W of mARC-2 and N-reductive activity of 2SF, D14G, K16E, and T22A of cytochrome b5 type B were analyzed. Western blot analyses were consistent with the hypothesis that the mARC-containing N-reductive enzyme system might be involved in the reduction of SMX-HA. In agreement with these results, highest reduction rates were found in mitochondrial subcellular fractions of porcine tissue and in the outer membrane vesicle (OMV) of human liver tissue. Knockdown studies in HEK-293 cells demonstrated that mARC-1 and mARC-2 were capable of reducing SMX-HA in cell metabolism. Investigations with the heterologously expressed human mARC-2 protein showed a higher catalytic efficiency toward SMX-HA than mARC-1, but none of the investigated human protein variants showed statistically significant differences of its N-reductive activity and was therefore likely to participate in the pathogenesis of hypersensitivity reaction under treatment with SMX. (Chemical Equation Presented).

Synthesis of calix[4]azacrown substituted sulphonamides with antioxidant, acetylcholinesterase, butyrylcholinesterase, tyrosinase and carbonic anhydrase inhibitory action

Akocak, Suleyman,Boga, Mehmet,Kalay, Erbay,Lolak, Nebih,Nocentini, Alessio,Oguz, Mehmet,Supuran, Claudiu T.,Yilmaz, Mustafa

, p. 1215 - 1223 (2020/05/27)

A series of novel calix[4]azacrown substituted sulphonamide Schiff bases was synthesised by the reaction of calix[4]azacrown aldehydes with different substituted primary and secondary sulphonamides. The obtained novel compounds were investigated as inhibitors of six human (h) isoforms of carbonic anhydrases (CA, EC 4.2.1.1). Their antioxidant profile was assayed by various bioanalytical methods. The calix[4]azacrown substituted sulphonamide Schiff bases were also investigated as inhibitors of acetylcholinesterase (AChE), butyrylcholinesterase (BChE) and tyrosinase enzymes, associated with several diseases such as Alzheimer, Parkinson, and pigmentation disorders. The new sulphonamides showed low to moderate inhibition against hCAs, AChE, BChE, and tyrosinase enzymes. However, some of them possessed relevant antioxidant activity, comparable with standard antioxidants used in the study.

Industrial preparation method of Sinomin

-

Paragraph 0015-0018, (2019/01/13)

The invention discloses an industrial preparation method of Sinomin. According to the industrial preparation method, 3-amino-5-methylisoxazole and diphenyl urea sulfonyl chloride are used as raw materials, under the condition of basicity, condensation reaction is performed at first, then hydrolysis, acidification, concentration under reduced pressure, centrifugation and drying are performed so asto prepare the Sinomin. The used raw materials are easy to obtain, the preparation method is low-cost, post-treatment is simple, the finished product does not need to be recrystallized, the reaction operation is highly safe, product purity is greater than or equal to 99.5%, the yield of the product is 92-95%, the preparation method does not contaminate environment heavily, so that the industrial preparation method is based on the principle of green chemistry, and is easy to industrialize.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 723-46-6